Visit this section

For those with severe CUD, quitting cannabis entirely is often the best approach. However, a gradual reduction in use – rather than abrupt cessation – can help ease withdrawal symptoms, improve treatment adherence, and reduce the risk of relapse.

Currently, CBD is not recommended for treating schizophrenia.

While cannabidiol (CBD) is being researched for its potential therapeutic effects, combining it with antipsychotic medications may lead to unwanted side effects due to drug-drug interactions.

Both CBD and many antipsychotics are metabolized by the same liver enzymes, which can interfere with their effectiveness. This competition can either increase side effects or reduce the effectiveness of antipsychotic medications.

Until more research confirms its safety and benefits, the usage of CBD in schizophrenia treatment should be taken with caution.

Cannabis use is a major factor that can lead to medication nonadherence in psychiatric patients.

For those with both schizophrenia and CUD, the key management strategies include:

  • Encouraging patients to gradually reduce cannabis use by switching to lower-potency strains and decreasing frequency.
  • Prescribing antipsychotics with partial dopaminergic agonist mechanisms, rather than first-generation antipsychotics, as they may improve outcomes for individuals with schizophrenia and CUD.
  • A recent observational study found that newer antipsychotic medications not only helped reduce schizophrenia symptoms but also improved self-reported struggles with cannabis use.
  • Enhancing medication adherence through digital reminders and carefully balancing medications to ensure they are effective and well-tolerated.

By combining medical support with behavioral strategies, patients with schizophrenia and CUD can experience better symptom management and improved quality of life.

Showing 0 result(s).